# Dermata Therapeutics, Inc.: financial statements, quarterly

DRMA · Nasdaq · CIK 1853816 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/drma.md) · [Financials](/companies/drma/financials.md) · [Filings](/companies/drma/filings.md) · [Insiders](/companies/drma/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/drma/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [903](/filings/0001654954-24-014274.md) | [1,135 d](/filings/0001654954-25-002885.md) | [1,601](/filings/0001641172-25-010111.md) | [2,009](/filings/0001641172-25-023572.md) | [2,401](/filings/0001493152-25-023474.md) | [2,192 d](/filings/0001493152-26-012992.md) | [1,281](/filings/0001493152-26-022719.md) | [618](/filings/0001493152-26-037127.md) | [504](/filings/0001493152-25-023474.md) | [527 d](/filings/0001493152-26-012992.md) | [384](/filings/0001493152-26-022719.md) | [213](/filings/0001493152-26-037127.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | [824](/filings/0001493152-25-023474.md) | [1,008 d](/filings/0001493152-26-012992.md) | [1,059](/filings/0001493152-26-022719.md) | [1,155](/filings/0001493152-26-037127.md) | [1,256](/filings/0001493152-25-023474.md) | [1,374 d](/filings/0001493152-26-012992.md) | [1,543](/filings/0001493152-26-022719.md) | [2,801](/filings/0001493152-26-037127.md) |
| Operating income | $k | [(1,812)](/filings/0001654954-24-014274.md) | [(2,220) d](/filings/0001654954-25-002885.md) | [(3,204)](/filings/0001641172-25-010111.md) | [(2,884)](/filings/0001641172-25-023572.md) | [(3,226)](/filings/0001493152-25-023474.md) | [(3,200) d](/filings/0001493152-26-012992.md) | [(2,340)](/filings/0001493152-26-022719.md) | [(1,773)](/filings/0001493152-26-037127.md) | [(1,761)](/filings/0001493152-25-023474.md) | [(1,900) d](/filings/0001493152-26-012992.md) | [(1,926)](/filings/0001493152-26-022719.md) | [(3,014)](/filings/0001493152-26-037127.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,719)](/filings/0001654954-24-014274.md) | [(2,134) d](/filings/0001654954-25-002885.md) | [(3,134)](/filings/0001493152-25-023474.md) | [(2,829)](/filings/0001493152-25-023474.md) | [(3,173)](/filings/0001493152-25-023474.md) | [(3,151) d](/filings/0001493152-26-012992.md) | [(2,304)](/filings/0001493152-26-037127.md) | [(1,701)](/filings/0001493152-26-037127.md) | [(1,692)](/filings/0001493152-25-023474.md) | [(1,862) d](/filings/0001493152-26-012992.md) | [(1,848)](/filings/0001493152-26-037127.md) | [(2,967)](/filings/0001493152-26-037127.md) |
| Diluted EPS | $ per share | not reported | not reported | [(7.06)](/filings/0001641172-25-010111.md) | [(41.82)](/filings/0001641172-25-023572.md) | [(20.41)](/filings/0001493152-25-023474.md) | not reported | [(4.47)](/filings/0001493152-26-022719.md) | [(1.66)](/filings/0001493152-26-037127.md) | [(1.65)](/filings/0001493152-25-023474.md) | not reported | [(0.48)](/filings/0001493152-26-022719.md) | [(0.74)](/filings/0001493152-26-037127.md) |
| Basic EPS | $ per share | [(0.54)](/filings/0001654954-23-014016.md) | not reported | [(7.06)](/filings/0001641172-25-010111.md) | [(41.82)](/filings/0001641172-25-023572.md) | [(20.41)](/filings/0001493152-25-023474.md) | not reported | [(4.47)](/filings/0001493152-26-022719.md) | [(1.22)](/filings/0001493152-26-037127.md) | [(1.65)](/filings/0001493152-25-023474.md) | not reported | [(0.48)](/filings/0001493152-26-022719.md) | [(0.74)](/filings/0001493152-26-037127.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.6](/filings/0001654954-23-014016.md) | not reported | not reported | not reported | not reported | [3.2](/filings/0001493152-26-012992.md) | [9.7](/filings/0001641172-25-010111.md) | [6.5](/filings/0001641172-25-023572.md) | [4.7](/filings/0001493152-25-023474.md) | [7.5](/filings/0001493152-26-037127.md) | [6.9](/filings/0001493152-26-022719.md) | [4.4](/filings/0001493152-26-037127.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [7.9](/filings/0001493152-26-037127.md) | not reported | [5.2](/filings/0001493152-26-037127.md) |
| Total assets | $m | [7.3](/filings/0001654954-23-014016.md) | [8.0](/filings/0001654954-25-002885.md) | [5.2](/filings/0001654954-24-006398.md) | [5.2](/filings/0001654954-24-010103.md) | [6.7](/filings/0001654954-24-014274.md) | [3.5](/filings/0001493152-26-012992.md) | [10.0](/filings/0001641172-25-010111.md) | [6.6](/filings/0001641172-25-023572.md) | [5.1](/filings/0001493152-25-023474.md) | [7.9](/filings/0001493152-26-037127.md) | [7.5](/filings/0001493152-26-022719.md) | [5.3](/filings/0001493152-26-037127.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [0.9](/filings/0001654954-23-014016.md) | [1.6](/filings/0001654954-25-002885.md) | [1.4](/filings/0001654954-24-006398.md) | [1.9](/filings/0001654954-24-010103.md) | [1.9](/filings/0001654954-24-014274.md) | [2.0](/filings/0001493152-26-012992.md) | [2.7](/filings/0001641172-25-010111.md) | [1.0](/filings/0001641172-25-023572.md) | [1.1](/filings/0001493152-25-023474.md) | [1.6](/filings/0001493152-26-037127.md) | [1.1](/filings/0001493152-26-022719.md) | [1.8](/filings/0001493152-26-037127.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.4](/filings/0001654954-24-014274.md) | [6.4](/filings/0001493152-26-012992.md) | [3.8](/filings/0001493152-25-023474.md) | [3.3](/filings/0001493152-25-023474.md) | [4.7](/filings/0001493152-25-023474.md) | [1.6](/filings/0001493152-26-037127.md) | [7.3](/filings/0001493152-26-037127.md) | [5.6](/filings/0001493152-26-037127.md) | [4.0](/filings/0001493152-25-023474.md) | [6.2](/filings/0001493152-26-037127.md) | [6.4](/filings/0001493152-26-037127.md) | [3.5](/filings/0001493152-26-037127.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,772) d](/filings/0001654954-24-014274.md) | [(1,147) d](/filings/0001654954-25-002885.md) | [(2,704)](/filings/0001641172-25-010111.md) | [(2,126) d](/filings/0001641172-25-023572.md) | [(3,419) d](/filings/0001493152-25-023474.md) | [(2,914) d](/filings/0001493152-26-012992.md) | [(1,934)](/filings/0001493152-26-022719.md) | [(2,690) d](/filings/0001493152-26-037127.md) | [(1,804) d](/filings/0001493152-25-023474.md) | [(1,372) d](/filings/0001493152-26-037127.md) | [(2,480)](/filings/0001493152-26-022719.md) | [(2,422) d](/filings/0001493152-26-037127.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [444](/filings/0001641172-25-010111.md) | [67.7](/filings/0001641172-25-023572.md) | [155](/filings/0001493152-25-023474.md) | [515](/filings/0001493152-26-022719.md) | [1,027](/filings/0001493152-26-037127.md) | [1,026](/filings/0001493152-25-023474.md) | [3,859](/filings/0001493152-26-022719.md) | [4,022](/filings/0001493152-26-037127.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,022,143 at 2026-08-10, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-037127.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.